Company intelligence / Profile preview
PathoVax
Baltimore, Maryland, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
PathoVax is developing RGVax, a broad-spectrum, potentially universal human papillomavirus (HPV) vaccine based on RG1-VLP technology licensed from Johns Hopkins University and Medical University of Vienna. Preclinical studies have shown protection against a broad range of high-risk HPV types, and an IND for the monovalent HPV16 RG1‑VLP component has been cleared by the FDA, enabling an academic-led, first‑in‑human, multicenter Phase 1 trial in the United States and Austria to evaluate safety and immunogenicity.[2][4]
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccineVirus-like particle vaccineRecombinant protein
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Johns Hopkins University (foundational technology licensing and collaboration)[2][4]Medical University of Vienna (foundational technology)[4]U.S. National Cancer Institute PREVENT Cancer Program (GMP and Phase 1 development support)[2][4]
Beyond the preview
Go deeper on PathoVax.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PathoVax.